CO-VELOCITY-GLOBAL
2.9.2020 07:04:13 CEST | Business Wire | Press release
Velocity Global , the leading provider of global expansion solutions, has selected Amsterdam, Netherlands, as the location for its European headquarters. The Denver-based company appointed Sander Poos as managing director of Europe based in Amsterdam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901006149/en/
As an International PEO, Velocity Global serves as an Employer of Record for supported employees in countries where clients have not set up a legal entity, enabling companies to compliantly expand internationally in a matter of weeks, and reduce their expansion costs.
“The number of clients expanding in Europe more than doubled this year compared to the same period in 2019,” said Velocity Global founder and CEO Ben Wright. “Even amidst a global pandemic, our growing clients also doubled the number of supported employees onboarded in Europe this year compared to the same period last year. Europe is critically important for both Velocity Global and our clients.”
The uptick in volume supports findings in Velocity Global’s 2020 State of Global Expansion™ report that 41 percent of tech companies in the U.S. and the UK targeted Europe as the most promising market to grow their customer base.
Amsterdam emerged as the natural choice for Velocity Global’s European headquarters as a business-friendly, culturally attractive city for international commerce. The city is geographically adjacent to key markets like Germany, France, and the United Kingdom. This year, in the final months of the Brexit transition, the European Union received approximately 80 percent of the European growth among Velocity Global clients, while the UK remains the top individual country destination.
Velocity Global established its Amsterdam presence in 2018, and now employs more than 30 team members in Europe serving in corporate and client-facing functions including client experience, employee support, operations, compliance, sales, finance, human resources, and legal.
Sander Poos leads Velocity Global’s team throughout Europe, reporting to Chief Operating Officer José Montero. He adds 25 years of experience in sales and operations in the human resources and software-as-a-service (SaaS) sectors. Poos most recently served as managing director of Benelux for Indeed.com, supporting operations in Amsterdam and Brussels as well as Dublin, Ireland. Previously he held leadership positions for companies including Xerox, Adecco, Monster.com, and Telegraaf Media Group.
“Sander brings a breadth of experience in successfully building people-focused business solutions across Europe,” said Montero. “His leadership balances revenue operations with industry-leading customer experience platforms putting people at the heart of his strategy.”
“New supported employees in Europe represent close to half of our global onboardings this year, a 40 percent increase over the first eight months of 2019,” said Poos. “I am excited to lead European growth for Velocity Global and our clients.”
The company's European team supports 19 languages from Europe, the Middle East, Africa, and Asia, contributing to the 36 languages supported worldwide by Velocity Global. Velocity Global has 250 employees located in 14 countries serving thousands of supported employees for clients in over 100 countries.
ABOUT VELOCITY GLOBAL
Velocity Global is the leading provider of global employment solutions that has reinvented the way companies expand overseas. With unrivaled expertise in over 185 countries, Velocity Global delivers end-to-end services and best-in-class support to help companies confidently navigate the entire lifecycle of international business. To ensure a compliant, efficient, and flexible international expansion, Velocity Global provides a comprehensive suite of global services that includes International PEO, Entity Setup and Support, Global Talent Acquisition, Immigration, and Consulting.
ABOUT SANDER POOS
Sander leads Velocity Global’s European team, responsible for the company’s business activities in the region, including all operations functions, customer experience, service delivery, and partner network alignment. He is a Dutch native based at the company’s European regional headquarters in Amsterdam.
Sander applies 25 years of experience in sales and operations in the human resources and software-as-a-service (SaaS) sectors. He most recently served as managing director of Benelux for Indeed.com, supporting operations in Amsterdam and Brussels as well as Dublin, Ireland. Previously, Sander held leadership positions for companies including Xerox, Adecco, Monster.com, and Telegraaf Media Group.
He received dual university degrees in Labor Market Politics and Personnel Policy, and Catholic Teaching from HAS Den Bosch University Holland, and an MBA from the Imperial College Business School in London. In his free time, he enjoys spending time with his family and playing tennis, and serves on the Board of the Dutch Tennis Association.
See biographies for Velocity Global leaders here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901006149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom